Vioxx litigation setbacks
Executive Summary
Atlantic City, N.J. state court judge sets aside a November verdict in favor of Merck and ordered a new trial for early next year, drug maker says Aug. 17. Decision comes after the New England Journal of Medicine asked Merck to submit a correction restating results of its Vioxx Gastrointestinal Outcomes Research (VIGOR) in a December Expression of Concern (1"The Pink Sheet" Dec. 12, 2005, p. 9). Jury in Humeston v. Merck had cleared the firm of allegations it failed to properly warn patients of risks associated with the use of rofecoxib. Company says it is currently mulling its legal options, which could include interlocutory appeal. Separately, a New Orleans jury awards $51 mil. in damages to the plaintiff in the second Vioxx federal lawsuit, a verdict the firm says it will challenge...
You may also be interested in...
Merck Will Need VIGOR To Defend Vioxx Data Following NEJM Claims
The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication
India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic
India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.
Products Distributed In Bulk Could Pump Up Already Large OTC Sanitizer Problem In US
“Regardless of whether the adulterated products are sold on store shelves, online to consumers, or in bulk format to businesses and other organizations, FDA’s priority is safety," says American Cleaning Institute VP James Kim.